| ID Source | ID |
|---|---|
| PubMed CID | 22641 |
| CHEMBL ID | 1367036 |
| CHEBI ID | 185822 |
| Synonym |
|---|
| isoalloxazine,8-dimethyl-, acetate |
| wln: t c666 bn dnvmv inj b2ov1 l1 m1 |
| mls000736493 , |
| nsc-3064 |
| 7,8-dimethyl-10-(2'-acetoxyethyl)isoalloxazine |
| 6266-58-6 |
| benzo[g]pteridine-2,3h)-dione, 10-[2-(acetyloxy)ethyl]-7,8-dimethyl- |
| 6,7-dimethyl-9-(2-acetoxyethyl)isoalloxazine |
| isoalloxazine,8-dimethyl-, acetate (ester) |
| nsc 3064 |
| 7,8-dimethyl-10-(2-acetoxyethyl)isoalloxazine |
| u 2112 |
| x 14 |
| 10-(2-acetoxyethyl)-7,8-dimethylisoalloxazine |
| nsc3064 |
| nsc-36854 |
| nsc36854 |
| ai3-26392 |
| isoalloxazine, 10-(2-hydroxyethyl)-7,8-dimethyl-, acetate (ester) |
| nsc 36854 |
| brn 0353592 |
| benzo(g)pteridine-2,4(1h,3h)-dione, 10-(2-(acetyloxy)ethyl)-7,8-dimethyl- |
| smr000528043 |
| isoalloxazine, 10-(2-hydroxyethyl)-7,8-dimethyl-, acetate |
| 2-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)ethyl acetate |
| CHEBI:185822 |
| NCGC00246786-01 |
| s0g6pb6sq2 , |
| unii-s0g6pb6sq2 |
| 5-26-14-00331 (beilstein handbook reference) |
| HMS2825O21 |
| CHEMBL1367036 |
| acetic acid 2-(7,8-dimethyl-2,4-dioxo-10-benzo[g]pteridinyl)ethyl ester |
| 2-[7,8-dimethyl-2,4-bis(oxidanylidene)benzo[g]pteridin-10-yl]ethyl ethanoate |
| cid_22641 |
| acetic acid 2-(2,4-diketo-7,8-dimethyl-benzo[g]pteridin-10-yl)ethyl ester |
| bdbm66626 |
| DTXSID50211720 |
| u-2112 |
| 10-(2-(acetyloxy)ethyl)-7,8-dimethylbenzo(g)pteridine-2,4(3h,10h)-dione |
| benzo(g)pteridine-2,4(3h,10h)-dione, 10-(2-(acetyloxy)ethyl)-7,8-dimethyl- |
| Class | Description |
|---|---|
| flavin | A derivative of the dimethylisoalloxazine (7,8-dimethylbenzo[g]pteridine-2,4(3H,10H)-dione) skeleton, with a substituent on the 10 position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 3.5481 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 5.0000 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 2.8184 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 39.8107 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| TDP1 protein | Homo sapiens (human) | Potency | 22.7265 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 3.9811 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 19.9526 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 0.7079 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 43.4228 | 0.7943 | 21.2757 | 50.1187 | AID624246; AID651803; AID651804 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 3.5481 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 2.2387 | 0.6561 | 9.4520 | 25.1189 | AID463254 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 0.8437 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 3.9811 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
| snurportin-1 | Homo sapiens (human) | Potency | 39.8107 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 2.8184 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 6.9578 | 0.1298 | 10.8331 | 32.6090 | AID493005; AID651599; AID651600 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 7.9433 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0388 | 14.3501 | 43.6206 | AID2676 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 69.6219 | 6.3096 | 60.2008 | 112.2020 | AID720707; AID720709 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 10.0000 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 69.9053 | 3.9811 | 46.7448 | 112.2020 | AID720708; AID720711 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | IC50 (µMol) | 18.7600 | 0.4000 | 7.1344 | 54.0000 | AID1418 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 18.7600 | 0.0005 | 2.7739 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 18.7600 | 0.0005 | 2.8919 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 18.7600 | 0.0005 | 2.7478 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 18.7600 | 0.0005 | 2.7802 | 25.1700 | AID1418 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 18.7600 | 0.0005 | 3.3142 | 49.5000 | AID1418 |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | IC50 (µMol) | 515.6500 | 0.0537 | 3.0757 | 10.0000 | AID1440267; AID1440271 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, BCL-2-RELATED PROTEIN A1 | Homo sapiens (human) | EC50 (µMol) | 350.0000 | 8.0570 | 121.1218 | 338.0000 | AID2765 |
| MSRA protein | Bos taurus (cattle) | EC50 (µMol) | 54.3730 | 3.6370 | 4.0500 | 4.4630 | AID623963 |
| insulin-degrading enzyme isoform 1 | Homo sapiens (human) | EC50 (µMol) | 54.6860 | 2.0260 | 5.1785 | 8.9430 | AID588439; AID588681 |
| bcl-2-like protein 11 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 350.0000 | 8.0570 | 121.1218 | 338.0000 | AID2765 |
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7 | Homo sapiens (human) | AC50 | 15.3300 | 0.0398 | 15.0025 | 50.0000 | AID743267 |
| LANA | Human gammaherpesvirus 8 | AC50 | 0.2940 | 0.0420 | 32.4569 | 312.0010 | AID504725; AID504727 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1440268 | Inhibition of recombinant human IDO1 expressed in bacterial expression system at 20 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440271 | Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) using L-Tryptophan as substrate after 25 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440270 | Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) at 20 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440272 | Selectivity ratio of IC50 for recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) to IC50 for recombinant human IDO1 expressed in bacterial expression system | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| AID1440267 | Inhibition of recombinant human IDO1 expressed in bacterial expression system using L-Tryptophan as substrate after 25 mins in absence of GSH and presence of tween20 by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||